Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab

Roche’s Genentech has notched another success on its way to challenging Regeneron — as well as the other Big Pharma contender Novartis — for the blockbuster crown now worn by Eylea.